Reported Late Thursday April 6, MRNA Cancer Vaccine MRNA-4157/V940 In Combination With Keytruda, Receives Prime Scheme Designation From the European Medicines Agency For Adjuvant Treatment Of Patients With High-Risk Stage III/IV Melanoma
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / April 6, 2023